<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011943</url>
  </required_header>
  <id_info>
    <org_study_id>TFM3</org_study_id>
    <nct_id>NCT04011943</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for Health Improvement (TFM3)</brief_title>
  <acronym>TFM3</acronym>
  <official_title>Study of the Effects of Fecal Microbiota Transplantation for Correction of the Physiological State of the Human Body in Norm and in Pathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research and Clinical Center of Physical-Chemical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research and Clinical Center of Physical-Chemical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Search for mechanisms of the effect of fecal transplantation on a healthy organism and
      various nosological forms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives of the study:

        1. To select donors of fecal samples for carrying out the procedure of fecal
           transplantation of microbiota to patients with various nosological forms.

        2. To select healthy volunteers for autologous and heterologous transfusion of feces and a
           group of placebo-control.

        3. Create a bank of fecal samples of healthy donors;

        4. Conduct a procedure for fecal microbiota transplantation for a sample of patients and
           healthy volunteers;

        5. Analyze the efficacy of therapy with TFM on the sample of patients;

        6. Analyze the effect of autologous, heterologous TFM and placebo on healthy volunteers;

        7. Analyze long-term effects in patients within 6 months after the TPM.

      The study is expected to include 50 patients, 35 healthy volunteers and healthy feces donors
      The study is scheduled to begin in May 2018, the supposed completion of the study is December
      2020
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In total, 85 participants must be registered. 35 are healthy volunteers. Of these volunteers, 15 will receive autologous transplantation of fecal microbiota, 10 will receive both autologous and heterologous transplantation and 10 volunteers form a placebo-controlled group.
50 participants will form a treatment group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ulcerative Colitis remission</measure>
    <time_frame>1 month after transplantation. Change from Baseline - 1 day before transplantation</time_frame>
    <description>Ulcerative Colitis remission defined as a Simple Clinical Colitis Activity Index &lt;3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Crohn Disease remission</measure>
    <time_frame>1 month after transplantation. Change from Baseline - 1 day before transplantation.</time_frame>
    <description>Crohn Disease remission defined as a Harvey-bradshaw index &lt;3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Ulcerative Colitis symptoms.</measure>
    <time_frame>1 month after transplantation. Change from Baseline - 1 day before transplantation.</time_frame>
    <description>Defined as improvement in SCCAI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiome</measure>
    <time_frame>1 month after transplantation. Change from Baseline - 1 day before transplantation.</time_frame>
    <description>Diversity and variability of gut microbiome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Crohn Disease</condition>
  <condition>Irritable Bowel</condition>
  <arm_group>
    <arm_group_label>Participants with bowel diseases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by transplantation of fecal microbiota</description>
  </arm_group>
  <arm_group>
    <arm_group_label>autologous transplantation of fecal microbiota - healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Both autologous and heterologous transplantation - healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive both autologous and heterologous transplantation (capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo capsules - healthy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers will receive placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Fecal Microbiota Transplantation</description>
    <arm_group_label>Both autologous and heterologous transplantation - healthy</arm_group_label>
    <arm_group_label>Participants with bowel diseases</arm_group_label>
    <arm_group_label>autologous transplantation of fecal microbiota - healthy</arm_group_label>
    <arm_group_label>placebo capsules - healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the age of patients - from 18 to 75 years, both sexes;

          -  Patients with:

               -  antibiotic-associated colitis,

               -  inflammatory bowel diseases (ulcerative colitis, Crohn's disease),

               -  diseases caused by C. difficile infection,

               -  a syndrome of impaired intestinal absorption,

               -  irritable bowel syndrome,

               -  celiac disease (severe form),

               -  metabolic syndrome, including diabetes mellitus type II,

               -  Atopic dermatitis with damage to the mucous membrane of the colon,

               -  hepatitis of various etiologies,

               -  cirrhosis of the liver of various etiologies

               -  pancreatitis of various etiologies,

          -  Absence of contraindications to gastroscopy

          -  informed consent of the patient for the transplant procedure

        Exclusion Criteria:

          -  the presence of a concomitant chronic infectious or neoplastic disease in the patient

          -  Patients with a proven allergy to foods not excluded from the donor's diet

          -  absence of the patient for one or more intermediate stages of the examination.

          -  informed refusal to continue therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Ilina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FRCC PCM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FRCC PCM</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

